Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-03-04

Clinical Trial Update: RNF and Betaseron® Tolerability Study [Phase 3]

View source ↗

Summary

A Phase 3 tolerability study evaluating RNF and Betaseron in relapsing-remitting multiple sclerosis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Betaseron (Interferon beta-1b)
  • RNF

Snippet

Sponsor: EMD Serono | Conditions: Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Status: COMPLETED | Results posted: 2010-03-04